Protagonist Therapeutics Share Price (NASDAQ: PTGX)

$58.99

▲

0.85

(1.46%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Protagonist Therapeutics Stock chart to analyse performance

Protagonist Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$57.78
Today's High:$59.11
$58.99
2.05%
Downside
Day's Volatility :2.25%
Upside
0.2%
52 Weeks Low:$33.31
52 Weeks High:$61.89
$58.99
43.53%
Downside
52 Weeks Volatility :46.18%
Upside
4.69%

Protagonist Therapeutics Stock Returns

Period	Protagonist Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	17.63%	3.6%	0.0%
6 Months	53.22%	-7.7%	0.0%
1 Year	42.45%	-12.6%	0.0%
3 Years	542.59%	9.5%	-4.7%

Protagonist Therapeutics Inc Key Stats

Check Protagonist Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$58.14
Open	$58.3
Today's High	$59.11
Today's Low	$57.78
Market Capitalization	$3.8B
Today's Volume	$792.3K
52 Week High	$61.89
52 Week Low	$33.31
Revenue TTM	$209.2M
EBITDA	$24.9M
Earnings Per Share (EPS)	$0.73
PE Ratio	79.64
Profit Margin	24.88%
Quarterly Earnings Growth YOY	3.51%
Return On Equity TTM	8.61%

Stock Returns calculator for Protagonist Therapeutics Stock including INR - Dollar returns

The Protagonist Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Protagonist Therapeutics investment value today

Current value as on today

₹1,42,822

Returns

₹42,822

(+42.82%)

Returns from Protagonist Therapeutics Stock

₹37,538 (+37.54%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Protagonist Therapeutics Stock

-24%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Protagonist Therapeutics Stock from India on INDmoney has decreased by -24% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Protagonist Therapeutics Inc

Name
Holdings %
Name
Holdings %
BlackRock Inc
15.65%
Farallon Capital Management, L.L.C.
9.82%
RTW INVESTMENTS, LLC
9.25%
Vanguard Group Inc
7.01%
Deep Track Capital, LP
5.22%
Bvf Inc
5.16%

Analyst Recommendation on Protagonist Therapeutics Stock

Rating

Trend

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Protagonist Therapeutics(by analysts ranked 0 to 5 stars)

Protagonist Therapeutics Share Price Target

What analysts predicted

Upside of 18.2%

Target:

$69.73

Current:

$58.99

Protagonist Therapeutics share price target is $69.73, a slight Upside of 18.2% compared to current price of $58.99 as per analysts' prediction.

Protagonist Therapeutics Stock Insights

Price Movement
In the last 6 months, PTGX stock has moved up by 56.9%
PTGX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 32.4%
Price to Sales
ForPTGX every $1 of sales, investors are willing to pay $17.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Protagonist Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$231.0K	↓ 99.25%
Net Income	$-77.2M	↑ 98.3%
Net Profit Margin	-33.4K%	↓ 33288.42%

	FY20	Y/Y Change
Revenue	$28.6M	↑ 12293.07%
Net Income	$-66.2M	↓ 14.3%
Net Profit Margin	-231.07%	↑ 33183.22%

	FY21	Y/Y Change
Revenue	$27.4M	↓ 4.44%
Net Income	$-122.6M	↑ 85.38%
Net Profit Margin	-448.25%	↓ 217.18%

	FY22	Y/Y Change
Revenue	$26.6M	↓ 2.84%
Net Income	$-123.4M	↑ 0.64%
Net Profit Margin	-464.29%	↓ 16.04%

	FY23	Y/Y Change
Revenue	$60.0M	↑ 125.73%
Net Income	$-79.0M	↓ 36.02%
Net Profit Margin	-131.59%	↑ 332.7%

	FY24	Y/Y Change
Revenue	$434.4M	↑ 624.05%
Net Income	$275.2M	↓ 448.54%
Net Profit Margin	63.34%	↑ 194.93%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$255.0M	↑ 324.92%
Net Income	$207.3M	↑ 658.51%
Net Profit Margin	81.32%	↑ 35.76%

	Q2 FY24	Q/Q Change
Revenue	$4.2M	↓ 98.37%
Net Income	$-30.6M	↓ 114.77%
Net Profit Margin	-734.73%	↓ 816.05%

	Q3 FY24	Q/Q Change
Revenue	$4.7M	↑ 12.19%
Net Income	$-33.2M	↑ 8.47%
Net Profit Margin	-710.37%	↑ 24.36%

	Q4 FY24	Q/Q Change
Revenue	$170.6M	↑ 3550.01%
Net Income	$131.7M	↓ 496.49%
Net Profit Margin	77.17%	↑ 787.54%

	Q1 FY25	Q/Q Change
Revenue	$28.3M	↓ 83.4%
Net Income	$-11.7M	↓ 108.85%
Net Profit Margin	-41.15%	↓ 118.32%

	Q2 FY25	Q/Q Change
Revenue	$5.5M	↓ 80.42%
Net Income	$-34.8M	↑ 198.34%
Net Profit Margin	-626.96%	↓ 585.81%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$231.0K	↓ 99.25%

	FY20	Y/Y Change
Profit	$28.6M	↑ 12293.07%

	FY21	Y/Y Change
Profit	$24.6M	↓ 14.13%

	FY22	Y/Y Change
Profit	$26.6M	↑ 8.13%

	FY23	Y/Y Change
Profit	$60.0M	↑ 125.73%

	FY24	Y/Y Change
Profit	$431.5M	↑ 619.12%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Profit	$254.1M	↑ 329.51%

	Q2 FY24	Q/Q Change
Profit	$3.3M	↓ 98.71%

	Q3 FY24	Q/Q Change
Profit	$4.7M	↑ 42.75%

	Q4 FY24	Q/Q Change
Profit	$170.0M	↑ 3537.09%

	Q1 FY25	Q/Q Change
Profit	$28.3M	↓ 83.34%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-41.5M	↓ 16.86%
Investing Cash Flow	$-53.7M	↓ 2527.02%
Financing Cash Flow	$46.0M	↑ 90.9%

	FY20	Y/Y Change
Operating Cash Flow	$-72.5M	↑ 74.55%
Investing Cash Flow	$-91.0M	↑ 69.36%
Financing Cash Flow	$247.6M	↑ 437.9%

	FY21	Y/Y Change
Operating Cash Flow	$-107.9M	↑ 48.81%
Investing Cash Flow	$-15.9M	↓ 82.56%
Financing Cash Flow	$129.9M	↓ 47.53%

	FY22	Y/Y Change
Operating Cash Flow	$-108.1M	↑ 0.25%
Investing Cash Flow	$91.5M	↓ 676.72%
Financing Cash Flow	$18.8M	↓ 85.5%

	FY23	Y/Y Change
Operating Cash Flow	$-70.2M	↓ 35.05%
Investing Cash Flow	$-39.3M	↓ 142.92%
Financing Cash Flow	$170.5M	↑ 804.96%

	FY24	Y/Y Change
Operating Cash Flow	$184.2M	↓ 362.19%
Investing Cash Flow	$-299.5M	↑ 662.86%
Financing Cash Flow	$25.9M	↓ 84.83%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-27.4M	↓ 261.73%
Investing Cash Flow	$6.1M	↓ 109.91%
Financing Cash Flow	$7.2M	↑ 1266.03%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$268.6M	↓ 1079.34%
Investing Cash Flow	$-88.1M	↓ 1551.47%
Financing Cash Flow	$2.6M	↓ 64.27%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-27.9M	↓ 110.37%
Investing Cash Flow	$-208.7M	↑ 136.85%
Financing Cash Flow	$12.1M	↑ 368.55%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-29.2M	↑ 4.72%
Investing Cash Flow	$-8.7M	↓ 95.82%
Financing Cash Flow	$4.0M	↓ 66.55%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$125.4M	↓ 529.65%
Investing Cash Flow	$-94.4M	↑ 981.97%
Financing Cash Flow	$11.4M	↑ 183.87%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-28.8M	↓ 122.96%
Investing Cash Flow	$54.8M	↓ 158.06%
Financing Cash Flow	$2.9M	↓ 74.44%

Protagonist Therapeutics Technicals Summary

Sell

Neutral

Buy

Protagonist Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Protagonist Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Protagonist Therapeutics Inc	9.59%	53.22%	42.45%	542.59%	181.31%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Protagonist Therapeutics Inc	79.64	79.64	0.0	-1.98	0.09	0.02	NA	10.76
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Protagonist Therapeutics Inc	Buy	$3.8B	181.31%	79.64	24.88%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Organization	Protagonist Therapeutics
Employees	130
CEO	Dr. Dinesh V. Patel Ph.D.
Industry	Health Technology

Key Management of Protagonist Therapeutics Inc

Name	Title
Dr. Dinesh V. Patel Ph.D.	CEO, President, Secretary & Director
Mr. Asif Ali	Executive VP & CFO
Dr. Suneel K. Gupta Ph.D.	Executive Vice President of Clinical Development
Dr. Arturo M. Molina FACP, M.D., M.S.	Chief Medical Officer
Mr. Mohammad Masjedizadeh Ph.D.	Executive VP & CTO
Dr. Newman Yeilding	Executive VP, Chief Scientific Officer
Mr. Matthew M. Gosling J.D.	Executive VP & General Counsel
Ms. Carena Spivey	Head of HR & Senior VP of Human Resources
Dr. Ashok Bhandari Ph.D.	EVP & Chief Discovery Officer
Mr. Carter J. King	Executive Vice President of Business Development

Important FAQs about investing in PTGX Stock from India :

What is Protagonist Therapeutics share price today?

Protagonist Therapeutics share price today is $58.99 as on August 30, 2025 at 1:29 am IST at the close of the market. Protagonist Therapeutics share today touched a day high of $59.11 and a low of $57.78.

What is the 52 week high and 52 week low for Protagonist Therapeutics share?

Protagonist Therapeutics share touched a 52 week high of $61.89 and a 52 week low of $33.31. Protagonist Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $58.99, lower by 4.69% versus the 52 week high.

How to invest in Protagonist Therapeutics Stock (PTGX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Protagonist Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Protagonist Therapeutics Shares that will get you 0.0254 shares as per Protagonist Therapeutics share price of $58.99 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Protagonist Therapeutics Stock (PTGX) from India?

Indian investors can start investing in Protagonist Therapeutics (PTGX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Protagonist Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Protagonist Therapeutics share’s latest price of $58.99 as on August 30, 2025 at 1:29 am IST, you will get 0.1695 shares of Protagonist Therapeutics. Learn more about fractional shares .

What are the returns that Protagonist Therapeutics has given to Indian investors in the last 5 years?

Protagonist Therapeutics stock has given 181.31% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?